Chemo-free cancer treatments

- $IBRX is a company that is now treating bladder and lung cancers without chemotherapy - Their NK cell treatment was approved by the FDA this week - Despite these advancements, the stock is currently priced at $5 - More treatments and advancements are expected in the future - Company website: https://immunitybio.com/ - ImmunityBio is committed to increasing diversity in clinical trials to reduce disparities in healthcare - ImmunityBio's ANKTIVA receives FDA approval as a first-in-class immunotherapy for bladder cancer - ImmunityBio gains $300 million in non-dilutive capital for commercialization and pipeline expansion - ImmunityBio is developing immunotherapy products and cell therapies to strengthen the immune system and outsmart disease - ImmunityBio is researching cancer prevention with the National Cancer Institute - ImmunityBio's investigational cancer therapies and vaccines aim to activate various functions of the immune system for personalized treatment - ImmunityBio is continuously pursuing new immunotherapies to enhance the immune system and attack disease - ImmunityBio's NK-92® natural killer cell line provides a versatile testing tool for research scientists - ImmunityBio's personalized immunotherapies aim to strengthen the immune system for patients - ImmunityBio's platforms offer opportunities for trial investigators to contribute to clinical cancer research.

Summarized top reddit comments: - Momentum and awareness needed for chemo-free cancer treatments - Significant interest rate and short positions in play - Positive outlook on stock price reaching $10 or higher - FDA approval and effectiveness of Anktiva treatment highlighted - Investment opportunities and excitement in stock trading - Hope for success in investing and treatment of cancer without chemotherapy